Drug intelligence / Profile preview

Monad 1

Development stage: Unknown
Lead developer: Citius Pharmaceuticals
Administration: Topical

Overview

**Monad 1** is an investigational topical study intervention identified in Citius Pharmaceuticals' completed Phase 2 trial of CITI-002 for symptomatic treatment of Goligher grade II or III hemorrhoids. Public trial records list Monad 1 separately from Monad 2, Monad 3, and low- and high-dose CITI-002 combination arms, but do not publicly disclose Monad 1's active ingredient composition, dose, or molecular mechanism. It should therefore not be equated with Halo-Lido, the separately identified CITI-002 halobetasol-plus-lidocaine formulation. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT05348200))

Targets

GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Monad 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monad 1.

Explore the full profile